

Patch Testing in Adverse Drug Reactions

26

Margarida Gonçalo and Derk P. Bruynzeel

Contents

26.1 Introduction	1
26.1.1 Definition and Types of Cutaneous Adverse Drug Reactions	1
26.1.2 Main Clinical Patterns of Immune-Mediated CADR	2
26.1.3 Pathomechanisms Involved in Immune-Mediated Drug Eruptions	4
26.1.4 T-Cell Involvement in Drug Eruptions	4
26.2 The Workup in the Diagnosis of an Immune-Mediated CADR	5
26.2.1 Clinical Diagnosis and Drug Imputation	5
26.2.2 Complementary Tests to Confirm Drug Imputation	6
26.3 Patch Testing in CADR	7
26.3.1 The General Value of Patch Testing	7
26.3.2 Patch Test Technique	9
26.3.3 Material for Patch Testing with Drugs	10
26.3.4 Safety of Patch Testing	12
26.3.5 Specificity of Patch Test Reactions	12
26.3.6 Evaluating Cross-Reactivity on Patch Testing	12
26.4 Conclusions: Interpretation of Patch Test Results	13
26.5 Classic Articles and Monographs	13
References	14

26.1 Introduction

4

26.1.1 Definition and Types of Cutaneous Adverse Drug Reactions

5

6

A CADR is a skin eruption induced by drugs, systemic or topical drugs, used in adequate doses and in the correct indications. CADR are a frequent problem in Dermatology, but their incidence is not exactly known; 1–5% of inpatients experience such a reaction and it is a frequent cause of consultation in Dermatology [1–5]. Most CADR are mild, but about 20% can be severe and require hospitalization, for example, in patients with drug hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis which, apart from the skin, have involvement of other organs [5]. Considering its pathomechanism, CADR can be divided into several types. Most cases belong to type A and C, predictable and chemical, which represent an exaggerated pharmacologic activity of the drug, such as cheilitis from isotretinoin, or xerosis and papulo-pustulo-follicular reactions from inhibitors of epidermal growth factor receptor [6]. They can be enhanced by modification of drug bioavailability due to drug interactions, reduced metabolism, or elimination, especially in genetically susceptible individuals. Type D includes late (delayed) reactions, such as teratogenesis or carcinogenesis, and type E results from end-of-dose reactions [7]. Type B reactions are idiosyncratic, unexpected, unpredictable, and among these, many are due to immune reactions induced by the drug [5] (Table 26.1).

M. Gonçalo (✉)
Clinic of Dermatology, Coimbra University Hospital,
University of Coimbra, Praceta Mota Pinto,
3000-175 Coimbra, Portugal
e-mail: mmgoncalo@netcabo.pt

D.P. Bruynzeel
[AU1] Burg. Dedelstraat 42, 1391 GD Abcoude,
The Netherlands

Table 26.1 Main types of adverse drug reactions, according to its mechanism [7]

Type of adverse reaction	Mechanisms
A – Augmented	Exaggerated pharmacologic activity of the drug
B – Bizarre ^a	Idiosyncratic, unpredictable, usually immune-mediated
C – Chemical	Chemical or pharmacological effect of drug
D – Delayed	Reactions occurring late, related mainly with carcinogenesis or teratogenesis
E – End-of-doses	Reaction to drug suspension

^aThese are the ones that will be dealt with in this chapter

26.1.2 Main Clinical Patterns of Immune-Mediated CADR

Systemic exposure to drugs can sensitize the individual and lead to a wide variety of CADR or drug eruptions. Some reactions are not specifically induced by a drug, such as a maculopapular exanthema, urticaria or angioedema, lichenoid reaction, or subacute lupus erythematosus. Other patterns are almost exclusively induced by drugs (>90%), such as Stevens–Johnson syndrome, toxic epidermal necrolysis, fixed drug eruption, and acute generalized exanthematous pustulosis [5, 8].

According to their time course, drug eruptions can be divided into immediate reactions, occurring within minutes to 1–2 h of drug intake, and delayed reactions that occur several hours, days or up to 6 weeks after drug exposure. Immediate reactions present as urticaria, angioedema, or anaphylaxis, whereas for delayed reactions the clinical spectrum is much wider: maculopapular eruptions (the most frequent reaction pattern) (Fig. 26.1), exfoliative erythroderma, acute generalized exanthematous pustulosis (Fig. 26.2), localized fixed drug eruptions, Stevens–Johnson syndrome (Fig. 26.3), toxic epidermal necrolysis (Fig. 26.4), other bullous reactions mimicking pemphigus vulgaris or bullous pemphigoid, vasculitis, and lupus erythematosus [9].

Topically applied drugs may cause contact dermatitis reactions or photosensitive contact dermatitis. Topical sensitization and subsequent systemic exposure may induce skin reactions similar to systemic drug eruptions (maculopapular exanthema) [10] or patterns more typical of a systemic contact dermatitis,




Fig. 26.1 Generalized maculopapular exanthema from amoxicillin that developed on the ninth day of therapy, with symmetric lesions on the trunk (a) and targetoid lesions on the hands and forearms (b). This patient had positive patch tests with amoxicillin and ampicillin at 1 and 10% pet. and negative tests with penicillin G, dicloxacillin, and several cephalosporins

such as acrovesicular dermatitis, the “baboon syndrome” (see Chap. 17), or Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) [11, 12]. It is clear that in these situations patch testing can be of great help as a diagnostic tool [11].

67
68
69
70
71




Fig. 26.2 Acute generalized exanthematous pustulosis from ciprofloxacin, on the third day of evolution, with coalescent pustules on erythema, predominating on the main body folds (a). Patch tests were positive with ciprofloxacin at 10% pet. and also norfloxacin and lomefloxacin. The erythematous-vesicular reaction at D2 (b) changed into a pustular reaction at D3 (c). Histopathology showed an intraepidermal spongiform pustule as in the acute eruption

72 In patients with drug eruptions without previous
 73 contact sensitization, patch testing can also induce
 74 specific positive reactions, but the sensitivity of this



Fig. 26.3 Stevens–Johnson syndrome from lamotrigine, an anti-epileptic drug frequently responsible for this clinical reaction pattern, particularly in children. Note the typical oral involvement, with erosion of the whole semimucosa of the lower lip

test is much lower than in allergic contact dermatitis 75
 [13, 14]. The value of patch testing in CADR has not 76
 always been appreciated, but there is growing interest 77
 in this field. It is a safe method and results can be very 78
 rewarding, as positive test results can be very useful to 79
 confirm drug imputability established on clinical 80
 grounds. Patch testing can also be helpful for studying 81
 cross-reactions and understanding pathomechanisms 82
 involved in drug eruptions [15]. 83

Core Message

- Drug eruptions are adverse skin reactions caused by a drug used in normal doses. They present with a very wide variety of clinical patterns.



Fig. 26.4 Toxic epidermal necrolysis/Lyell's syndrome induced by carbamazepine. Note confluent flaccid bullae on the trunk, already with a few areas of epidermal detachment, and atypical target lesions in the arms. Although this is not frequent, this patient had positive patch tests to carbamazepine, which on histology had skin apoptosis of the whole epidermis, such as in the acute eruption of the toxic epidermal necrolysis

26.1.3 Pathomechanisms Involved in Immune-Mediated Drug Eruptions

In most CADR of the type B there is involvement of the immune system. Either antibodies or T-cells with their specific receptor recognize the drug, or a metabolite, or any of these combined with a peptide or with an autologous cell. These drug reactions can be classified according to the immunological reaction types of Gell and Coombs (see Chap. 3), but often it is not one isolated immunological mechanism that is responsible for the event: combinations of type I and IV hypersensitivity exist [16] and even more complex mechanisms can be involved [5, 17]. Genetic susceptibility is also important, as in cases of toxic epidermal necrolysis and Stevens–Johnson syndrome from allopurinol and carbamazepine and, particularly, in abacavir hypersensitivity syndrome, where HLA-B*5701 pretesting has significantly reduced this severe adverse reaction [18, 19].

Immediate reactions involve mainly drug-specific IgE and mast cell and basophil degranulation [20], whereas delayed reactions after systemic drug exposure depend mainly on type IV hypersensitivity reactions, with previous T-cell sensitization [21, 22]. By the clinical pattern and time course, we can suspect which mechanisms can be involved, but sometimes it is not possible [23].

The pseudo-allergic (anaphylactoid) reactions, including urticaria induced by acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs (NSAIDs) and angioedema induced by angiotensin converting enzyme inhibitors (ACEi), are examples of nonimmunological reactions mimicking a true (type I) allergic reaction. The most plausible explanation for these reactions is a nonspecific release of histamine and other mast cell and basophil mediators without the participation of IgEs or a reduced capacity to metabolize kinins, with consequent accumulation of the potent vasodilator bradykinin [24].

26.1.4 T-Cell Involvement in Drug Eruptions

Apart from allergic contact dermatitis and systemic contact dermatitis, delayed type IV hypersensitivity has been documented in maculopapular exanthema, in drug hypersensitivity syndrome/DRESS, in acute generalized exanthematous pustulosis, in the localized fixed drug eruption, and in the more extended bullous reactions in a continuum from Stevens–Johnson syndrome to toxic epidermal necrolysis [9]. These reactions usually begin within 7–21 days on the first exposure, but rechallenge is usually accelerated, positive with lower dose and more severe, suggesting specific immune sensitization. In the skin biopsies of the CADR there is mainly a dermo-epidermal infiltration of activated T-cells, some of which specifically recognize the drug or one of its metabolites. And, apart from the skin, drug-specific T-cells have been isolated from the blood or blister fluid during the acute reaction and also, later, from skin biopsies of positive patch tests [9, 25–28]. As previously referred, the clinical presentation of these CADR is very heterogeneous, even though there are data to support the involvement of delayed type hypersensitivity mechanisms [5]. Apart from other individual circumstances, this heterogeneity very probably depends on different pathways of drug recognition by the immune system and on the subtypes of effector T-cells. Although there is little knowledge on which cells participate in the process of drug presentation during the sensitization phase, the drug, a metabolite or both, can be recognized by the TCR combined with HLA molecules, either class I, class II, or both, with or without previous processing by the antigen presenting

155 cell [29]. There are many studies on the effector T-cells
 156 (Th1, Th2, Tcit) and on the main cytokines and
 157 chemokines involved in the final reaction (IFN-gama,
 158 IL-8, IL-5, eotaxin, TNF-alfa, Fas) [22, 30]. Recently,
 159 subtypes of type IV hypersensitivity have been defined
 160 in the participation of CADR [22, 31]. A Th1 pattern
 161 with IFN-gama production, considered a type IVa
 162 hypersensitivity, is mainly involved in allergic contact
 163 dermatitis and maculopapular exanthema. Type IVb
 164 involves mainly a Th2 response, with IL-5 and eotaxin
 165 production and, consequently, eosinophil recruitment
 166 and activation. Actually, there is eosinophil infiltra-
 167 tion in the dermis in maculopapular exanthema, and
 168 systemic eosinophilia is one of the criteria for drug
 169 hypersensitivity syndrome/DRESS [17, 32, 33]. In
 170 acute generalized exanthematous pustulosis, T-cells
 171 isolated from the blood and the skin produce high
 172 amounts of the chemokine CXCL8 (IL-8) and
 173 GM-CSF, with consequent preferential neutrophil
 174 recruitment that is responsible for the epidermal
 175 spongiform pustule typical of this CADR (type IVd
 176 hypersensitivity) [34, 35]. Type IVc, with predomi-
 177 nant T-cell cytotoxic activity, is involved at a lower
 178 level in maculopapular exanthems, but is very pro-
 179 nounced in Stevens–Johnson syndrome and toxic epi-
 180 dermal necrolysis, where keratinocyte apoptosis is the
 181 hallmark of the reaction [22, 36, 37]. Fixed drug eruptions
 182 are also typical T-cell-mediated reactions, with a
 183 special localization pattern and a very particular reten-
 184 tion of drug-specific T-cells in lesional areas. These
 185 resting T-cells are activated very shortly after topical
 186 or systemic drug exposure, and produce high amounts
 187 of IFN-gama and cytotoxic mediators (TNF-alfa and
 188 Fas), but precocious infiltration of regulatory T-cells
 189 (Tregs) seems to prevent its evolution to the more
 190 severe bullous reactions [38, 39]. Delayed type hyper-
 191 sensitivity is also involved in some photosensitive
 192 drug reactions, mainly in those with an eczematous
 193 pattern [40–42].

194 Therefore, the participation of drug-specific T-cells
 195 in several drug eruptions other than allergic contact
 196 dermatitis makes patch testing suitable for their study.
 197 Nevertheless, the rate of negative reactions is much
 198 higher, as mechanisms other than T-cell-derived hyper-
 199 sensitivity are involved, often in a more complex
 200 interplay with other systemic inflammatory reactions
 201 (viral infections, autoimmune diseases). Also in some
 202 CADRs, very probably, the allergen is not the drug
 203 itself, but a systemic metabolite and, although skin

204 metabolism is quite efficient, some drugs are not
 205 metabolized by skin cells [43]. And there are certainly
 206 other reasons, not completely understood, to explain
 207 many negative patch tests.

Core Message

› Many delayed drug eruptions are T-cell-mediated and, therefore, patch testing can be adequate in their study.

26.2 The Workup in the Diagnosis of an Immune-Mediated CADR

26.2.1 Clinical Diagnosis and Drug Imputation

212 The diagnosis of a drug eruption is easier if we are fac-
 213 ing a clinical pattern typical of a CADR, such as a
 214 fixed drug eruption, a toxic epidermal necrolysis, or a
 215 generalized exanthematous pustulosis. In nonspecific
 216 skin reactions patterns, a particular workup has to be
 217 done to exclude other causes for the rash, such as a
 218 viral infection in maculopapular exanthema or a non-
 219 drug allergen in acute urticaria or angioedema. In these
 220 situations, the diagnosis of drug eruption can be a
 221 diagnosis of exclusion.

222 In severe CADR, such as toxic epidermal necroly-
 223 sis, DRESS, and acute generalized exanthematous
 224 pustulosis, complementary tests are needed to evaluate
 225 the degree of systemic involvement.

226 At the time of diagnosis, it is extremely important
 227 to identify the culprit drug. In most CADRs, improve-
 228 ment depends on the drug suspension and prognosis
 229 depends mainly on an early drug withdrawal.

230 Imputation of the culprit drug is performed mainly
 231 on clinical grounds, based on extrinsic and intrinsic
 232 criteria. Extrinsic criteria include all previous reports
 233 of such a CADR. Intrinsic criteria are mainly based on
 234 the chronology and clinical characteristics of the
 235 adverse event: the clinical pattern of the eruption, its
 236 chronological relation with the initiation and suspen-
 237 sion of the drug, and information on previous drug
 238 exposure, with or without reaction (accidental rechal-
 239 lenge) [44, 45]. No single complementary test can
 240 replace a good characterization of these parameters.

Table 26.2 Main CADRs and the most adequate skin test according to each clinical pattern

CADR pattern	Expected free interval	Most adequate test to perform	
		In vivo	In vitro
Urticaria/angioedema anaphylaxis	Minutes to 1 h	Prick, i.d. ^a Oral challenge ^b	IgE (RAST/CAP) Basophil activation
Maculopapular exanthema	7–21 days 2 days ^c	Patch, i.d. ^a Oral challenge	LST/LTT
Drug hypersensitivity/DRESS	3–6 weeks	Patch i.d. ^d	LST/LTT ^e
Acute generalized exanthematic pustulosis	2–3 days	Patch	LST/LTT
Stevens–Johnson syndrome Toxic epidermal necrolysis	7–21 days 2 days ^c	Patch	LST/LTT
Fixed drug eruption	6–24 h	Lesional testing	
Systemic photosensitivity	2 days	Photopatch test Oral photoprovocation	

^aPerform i.d. tests only if prick or patch tests are negative

^bNot adequate in cases of anaphylaxis or severe angioedema

^cOn drug reintroduction

^di.d. is not advised, on a first basis, due to a possible severe reaction

^eLST/LTT (lymphocyte stimulation or transformation tests) are often negative during the acute phase of DRESS

But, even in the cases where very accurate data are available, the imputability or causality index for a single drug can be very low: many patients who develop a CADR are on multiple drugs; any drug can induce a drug eruption; different drugs can induce the same clinical pattern of drug eruption; and, the interval between drug initiation and development of the CADR can vary widely (6 h up to 6 weeks), even considering only delayed reactions (Table 26.2).

26.2.2 Complementary Tests to Confirm Drug Imputation

Drug reintroduction is considered the more definitive test for confirming the culprit drug, but it does not always reproduce the skin reaction [45, 46]; it is time-consuming when several drugs are suspected and it is contraindicated in severe reactions, such as toxic epidermal necrolysis or drug hypersensitivity syndrome/DRESS [45]. Therefore, complementary clinical and laboratory investigations have to be conducted in order to try to confirm, or deny, an imputable drug.

Laboratory tests, such as specific IgE or basophil activation, are used for the study of immediate reactions,

and lymphocyte transformation tests (LTT) or lymphocyte stimulation tests (LST) are used for studying mainly delayed hypersensitivity reactions [47]. They can help in the diagnosis, with the advantage of being an in vitro method that, in some circumstances, can be performed during the acute phase. Nevertheless, these tests are not available for most drugs, procedures are not standardized, results are inconsistent with undetermined sensitivity and specificity, and therefore, they are not performed on a routine basis [23, 47].

Skin testing can be used later, after the resolution of the CADR. It is important to choose the most adequate skin test, according to the reaction pattern, even though this is not always so straight. (Table 26.2) Tests with immediate readings, such as prick, scratch, or intradermal (i.d.) tests, are advised for immediate reactions such as urticaria and angioedema, whereas tests with delayed readings, such as the patch test, are mainly recommended for delayed skin reactions, e.g., eczematous reactions, maculopapular exanthema, erythroderma, drug hypersensitivity syndrome/DRESS, acute generalized exanthematous pustulosis, fixed drug eruption, Stevens–Johnson syndrome, and toxic epidermal necrolysis [15, 48]. Prick and i.d. tests with late readings, performed when patch tests are negative, may increase the effectiveness of skin testing. In two

separate studies these tests improved the diagnosis by about 10% in nonimmediate reactions from aminopenicillins and synergists [49, 50]. Commercial material for i.d. testing is not available for most drugs and, therefore, it has to be prepared, on a patient basis, in a sterilized setting, which is not always feasible. Moreover, in case of positive results, it may be difficult to use controls to evaluate the specificity of the reaction. Also, it is recommended to perform i.d. testing in a hospital setting, particularly in the study of severe CADR [51].

When positive, in vitro or in vivo tests can be of help in confirming which drug was responsible for the CADR, but, on the contrary, these tests are very seldom able to exclude the involvement of a drug.

26.3 Patch Testing in CADR

26.3.1 The General Value of Patch Testing

Patch testing in the study of drug eruptions has been performed for many years, but not as a systematic investigation in large multicenter investigational studies. There are a few studies with a relative large number of

patients patch tested with drugs [13, 51, 52] and they include a wide variety of patterns of drug eruptions. Nevertheless, the inclusion criteria are quite different and the imputability/causality index for the drugs studied (very probable/probable/possible) is not known in most cases. Also, as there are so many patterns and so many responsible drugs, it is difficult to ascertain the patch test reactivity and its real value (sensitivity and negative predicative value) in the many different settings.

While considering a wide range of drug eruptions, the frequency of positive tests varies from 7.5 to 54% [13, 14, 51–54]. Apart from patient selection, patch test reactivity depends mainly on the clinical pattern of the drug eruption and the drugs involved [51–54].

Patch tests are mostly positive in eczematous eruptions, systemic contact dermatitis, maculopapular, and erythroderma, and particularly, in more severe reactions [12, 14, 20, 51, 53, 55] (Table. 26.3).

In acute generalized exanthematous pustulosis there are many reports with positive patch tests, but with a few cases each [8, 26, 34, 35, 55–59]. In their study, Wolkenstein et al. found 50% of positive tests (7+out of the 14 patients tested) [60]. In this CADR, patch tests can show a pustular reaction with an epidermal spongiform pustule on skin biopsy, as in the acute reaction [26, 35, 56, 61] (Fig. 26.2b, c).

Table 26.3 Patch test results according to the type of eruption (adapted from Osawa et al. [52] Barbaud et al. [51] and Lamminatausta and Kortekangas-Savolainen [13])

CADR pattern	Number positive tests/number patients tested (%)			
	Osawa et al. [52] (n = 197)	Barbaud et al. [51] (n = 72)	Lammintausta et al. [13] (n = 826)	Other studies
Maculopapular	10/72 (14)	16/27 (59)	81/785 (10.3)	33/61 (54) [14]
Erythroderma	8/15 (53)	5/7 (71)		
Eczematous	9/17 (53)	3/9 (33)		
Erythema multiforme	6/29 (21)			
Lichenoid	2/11 (18)			
Photosensitivity		4/4 ^a (100)	2/12 (16.7)	
Fixed eruptions	2/6 (33)	0/3	8/28 (28.6)	26/30 (87) [68]
Urticaria/angioedema		2/18 (11)		
AGEP				7/14 (50) [60]
SJS/TEN				2/22 (9) [60]
Miscellaneous	15/47 (32)	1/6 ^b (17)		
Total	62/197 (31)	31/72 (43)	101/826 (12.2)	

^aPhotopatch test

^bPositive test in acute generalized exanthematous pustulosis

26

In DRESS, patch tests are often positive with abacavir [19, 62, 63] and antiepileptics, particularly carbamazepine [17, 64, 65] (Fig. 26.5). Patch test reactivity is much lower, below 10%, in Stevens–Johnson syndrome or toxic epidermal necrolysis [55, 60]. In some occasions histopathology of the patch test can also reproduce the full thickness epidermal apoptosis, such as in the acute reaction.

Fixed drug eruptions are unique in the persistence of drug-specific T-cells in residual skin lesions, so we can expect to find positive tests on these lesions, in a high percentage of cases [66–68], particularly, in fixed drug eruptions from NSAIDs [66, 69, 70] (Fig. 26.6). Alanko found as many as 26 positive tests out of 30 (87%) [68].

In photosensitive eruptions, when it is not a clearly phototoxic reaction, photopatch tests can be rewarding in the study of systemic photosensitivity as in photoallergic contact dermatitis [41, 42, 71, 72]. Piroxicam [40, 73–77], ketoprofen [71, 78], the fluorquinolones [42, 79, 80], and flutamide [81, 82] are examples of drugs that frequently elicit positive photopatch tests.

The reactivity of patch testing also depends on the culprit drug. Carbamazepine induces positive patch tests in more than 70% of the cases of delayed drug eruptions [51, 65, 83–86] (Fig. 26.5). High reactivity is also observed with tetrazepam [35, 51, 87–89], abacavir [19, 62, 63, 90], aminopenicillins [13, 20, 91], cephalosporins [13, 92], synergistines [50], cotrimoxazole [14]




Fig. 26.5 Positive reactions to carbamazepine tested at several concentrations (1–20% pet) in a patient with a severe exanthema in the context of a DRESS (drug reaction with eosinophilia and systemic symptoms). In this severe drug reaction it is advised to test carbamazepine only at 1% pet



Fig. 26.6 Lesional testing in a residual pigmented lesion of fixed drug eruption. Positive reaction with the NSAID, nimesulide, tested at 1% pet, presenting as erythema and infiltration. Note the negative reaction to another NSAID, tested at the left side, confirming the specific nature of the reaction

clindamycin [13, 93–95], (Fig. 26.7) diltiazem [14, 96–98], heparin derivatives [14, 99, 100], corticosteroids [101–103], pseudoephedrine [104], and hydroxyzine [14, 105, 106]. Nevertheless, contrary to the most regularly referred rate of 30–40% of positive reactions to betalactam antibiotics [51], in a recent review by Blanca et al., the rate of positive reactions was much lower (2.6%) [20], which is probably due to a different patient selection (Table 26.4).

The list of drugs reported to elicit positive patch or photopatch test reactions is increasing every day, as this method is increasingly being used in the diagnosis of drug eruptions.

Core Message

- Patch tests are more frequently positive in maculopapular exanthema, acute generalized exanthematous pustulosis, and fixed drug eruptions.



Fig. 26.7 Positive patch tests with clindamycin, the pure substance tested at 10% in pet.(upper test), with identical results when testing with the smashed content of the pills of clindamycin from two different brands (Dalacin C® and Clindamicina Atral®), both prepared at 10% in pet (lower reactions)

patch tests. It is not known exactly how long, but 6 weeks after complete resolution of the CADR is usually advised [15, 107]. Also, we do not know for how long skin sensitivity persists. Although some reactions are lost, many patients tested after 10 years still react positively [49]. Therefore, it is usually recommended to patch test within 6 weeks to 6 months [15].

Patch testing is performed in the generally accepted way on the back, as in the study of allergic contact dermatitis. In particular cases, as in fixed eruptions, reactivity occurs only in skin areas where the skin reaction has occurred [66, 108, 109]. The application time is usually 2 days, but occasionally it can be convenient to remove tests at D1 [49]. Readings are performed at D2 and at D3 or D4, and scored negative to 3+, according to the ICDRG guidelines.

In fixed drug eruptions, test materials are applied in duplicate: on an inactive, residual lesion and on the normal back skin, which serves as a negative control. The residual pigmentation is a useful marker to indicate the area to apply the test. Tests are usually applied for 1 day, with occlusion, as in patch testing. Readings are performed at D1 and D2, or at D3 if previously negative [66]. As sometimes positive reactions are seen only in the first 24 h, Alanko [68] prefers an open test, which makes observations possible during this period.

26.3.2 Patch Test Technique

It can take weeks before skin reactivity can be evaluated properly by patch testing. Thus, it is advisable to wait several weeks after the rash has gone to perform

Table 26.4 Patch test results in delayed CADR, according to the culprit drug

Culprit drug	Number positive reactions/number of patients tested (%)		
Betalactam antibiotics	4/24 (29) [53]		
Amoxicillin	10/247 (4) [13]	7/17 (41.2) [51]	
Cefalosporins	12/220 (4.1%) [13]		
Pristinamycin	7/8(87) [51]	17/20 (85) [13]	
Trimethoprim	10/163 (6.2%) [13]		
Cotrimoxazole	4/140 (2.9) [13]		
Clindamycin	12/63(19) [13]	5/33 (15) [94]	8/26 (31) ^a
Aciclovir	2/8(25) [45]		
Abacavir			7 [63] ^b
Carbamazepine	6+/7 (86) [53]	13/17 [64]	
Diltiazem	3/9(33.3) [13]	7/13 (54) [98]	
Allopurinol	1/10 (10) [13]	0/19 [64]	
Pseudoephedrine	5/16 (31.2) [13]		
Piroxicam (Photo)	75/82 (91.4) [73]		

^aPersonal data

^bOne study with seven positive patch tests [63]

A reaction is regarded as positive, if it occurs only in the residual lesion, and when clear erythema is visible for at least 6 h. Often there is erythema with infiltration (Fig. 26.6), eczema, or a bullous reaction that mimics the histopathology and clinical pattern of the acute fixed drug eruption [66, 70]. The reaction occurs exclusively in the area of application of the test or reactivation of the whole residual lesion can occur [66].

In systemic drug photosensitivity photoepicutaneous patch tests are performed, as in photoallergic contact dermatitis, using mainly UVA irradiation, at a dose of 5 J/cm² [41, 110, 111] (see Chap. 29).

26.3.3 Material for Patch Testing with Drugs

26.3.3.1 Patch Testing with Pure Drugs

In recent years, with the increasing interest in patch testing in drug eruptions, several firms that prepare allergens for the study of contact allergy are also producing standardized drug allergens with the pure active products. Of course, there is only a very limited number of drug allergens and every drug can induce a CADR. Nevertheless, the list includes drugs more frequently responsible for delayed CADRs: antibiotics, antiepileptic, NSAIDs, and some isolated drugs (Table 26.5). No controls are needed for these allergens, as many patients, who have been exposed to the drug with no reaction and, also nondrug exposed subjects, have been tested with no reaction.

This makes patch testing with drugs simple, allows testing several drugs at the same time and, particularly, testing with analogous chemicals to study cross-reactions and find possible replacement drugs. Actually, these studies have shown very interesting data on patterns of cross-reactivity that may be very informative for the patient and the doctor.

But, these commercialized drug allergens might be improved, as it is not known yet if the most correct concentrations or the most adequate vehicles are being used. Recommended concentrations are usually between 1 and 20% of the pure chemical, doses that are usually higher than in the study of allergic contact dermatitis. But for drugs, such as carbamazepine, low concentration, 1% or even below, can be enough [86, 112] (Fig. 26.5). Increasing concentration above 1 or 5%

pet. does not always increase patch test reactivity, as shown for carbamazepine and amoxicillin [49, 112]. For the 20% concentration, carbamazepine, hydrochlorothiazide, propranolol, sulphametoxazol, and thrimetoprim did not evoke reactions either when tested in 200 volunteers [1], or in previously exposed patients [65]. Although reactivation of the CADR during patch testing is exceptional [65] [144], in the case of a severe drug eruption, it is advisable to start with lower concentrations [15].

Also, there is not enough data on the best vehicle to perform patch testing. Most chemicals react when prepared in petrolatum, but in some cases water, ethanol, or acetone may be more adequate, as in the case of estradiol [10], or DMSO may be necessary to solubilize cotrimoxazole and its constituents [55, 113].

26.3.3.2 Patch Testing with Drugs Used by the Patient

If the pure drug is not available, which is often the case, patch testing can be done with the drug used by the patient, either a tablet, a capsule, or the solution for oral, i.v., or i.m. use. The amount of active drug in a tablet varies and can be very low. Therefore, it is preferable to use the content of a capsule or the powder for parenteral use, which usually have more active drug. This powder, or the fine powder obtained from smashing the pill after removing the external coating, can be diluted in petrolatum and water, or other vehicles, in a way to have the active drug in the final concentration at 10% (Fig. 26.7). If the concentration of the active drug is too low, it is recommended to prepare the smashed powder of the pill at 30% [15]. Of course, in this method, the final concentration of the active drug can vary a lot, but 30% is the highest concentration to obtain a homogenous preparation [15].

When tests are positive with these preparations, it is recommended to have serial dilutions and it is obligatory to test, at least, ten controls, preferably previously exposed individuals who have given their informed consent.

Even when tests have been done with pure chemicals, it can also be worthwhile to perform tests with the filler materials and the original drug preparation. In principle, reactions to the “inert” filler substances and additives are possible, but in practice they are rare [114–117].

Table 26.5 Commercially available drug allergens for patch testing

Group of drugs	Drug allergen	Concentration vehicle (% pet)	Company
Antibiotics	Penicillin G, potassium salt	10	CD
	Ampicillin	5	MT
	Amoxicillin trihydrate	10	CD
	Dicloxacillin sodium salt hydrate	10	CD
	Cefradine	10	CD
	Cefalexin	10	CD
	Cefotaxim sodium salt	10	CD
	Doxycyclin monohydrate	10	CD
	Minocycline hydrochloride	10	CD
	Erythromycin base	10	CD MT
	Spiramycin base	10	CD
	Clarithromycin	10	CD
	Pristinamycin	10	CD
	Cotrimoxazole	10	CD
	Norfloxacin	10	CD
	Ciprofloxacin hydrochloride	10	CD
	Clindamycin phosphate	10	CD
Antiepileptics	Carbamazepine	1	CD
	Hydantoin	10	CD
NSAIDs	Acetylsalicylic acid	10	CD MT
	Diclofenac sodium salt	1	CD Bi MT
	Ketoprofen	1	CD Bi Mt
	Naproxen	5	Bi MT
	Piroxicam	1	CD Bi MT
	Acetaminophen	10	CD Bi
	Ibuprofen	10	CD Bi MT
Miscellaneous	Acyclovir	10	CD
	Hydrochlorothiazide	1 and 10	CD
	Diltiazem hydrochloride	10	CD
	Captopril	5 ^a	CD

CD chemotechnique diagnostics, Malmö Sweden t5.33

MT Martí Tor, Dermatitis de Contacto, Barcelona, Spain t5.34

Bi Bial Aristégui, Bilbao, Spain t5.35

^aDoubtful reactions may occur with this concentration t5.36

26.3.4 Safety of Patch Testing

The risk of reactivation of the drug eruption is very low [14, 118], even in serious delayed CADR [64], but it has been occasionally reported with acyclovir, pseudoephedrin, pristinamycin [51], and carbamazepine, particularly when testing with the powder of the pills [119].

Serious immediate reactions evoked by patch testing are rare and have been described mainly in the study of anaphylaxis [120–122], particularly with penicillins, neomycin, or bacitracin. For safety reasons, it is practical to observe the patient for approximately half an hour after application of the test material.

The risk of patch testing is considerably lower compared with i.d. tests. Thus, the patch test is a good test to start with. If negative and, for the particular patient, it is important to prove the causality of the drug, the study can continue with the sequential use of prick, scratch, and i.d. tests with a delayed reading [15]. If all are negative, as a next step, a provocation test can be performed in a hospital setting, except if there is a contraindication, namely, a previous severe reaction, such as DRESS or toxic epidermal necrolysis, or the involvement of drugs as antiepileptics or salazosulfapyridine [45].

Another adverse patch test effect is sensitization by patch testing; this is rarely seen, even with penicillins [123].

26.3.5 Specificity of Patch Test Reactions

Positive patch test reactions, performed according to the recommendations [15], have been shown to be highly specific. Histopathology of drug patch tests is often analogous to the acute reaction [61, 124] and some T-cells that infiltrate the skin, in the patch test, specifically recognize the drug [25–28, 34]. Actually, drug-specific T-cells, with phenotypic and functional characteristics similar to those isolated from the blood or the skin during the acute phase of the CADR, have been isolated from positive patch tests with several drugs, such as amoxicillin, carbamazepine, lamotrigine, sulfonamides, fluorquinolones, and tetrazepam [25–28, 34, 35].

Patch testing with pure drugs or with low concentrations of the commercial products rarely yields false positive reactions. But, occasionally, constituents of the excipient of the commercial drug can cause false positive reactions due to irritation or low pH or they

can induce a nonrelevant positive patch test reaction in a previously contact sensitized patient [114]. For instance, false positive results have been observed with the powder of the pills of spironolactone (Aldactone®), colchicine, captopril (Lopril®), cloroquine (Nivaquine®), celecoxib (Celebrex®) tested at 30% pet, and with omeprazole (Mopral®) tested at 30% aq. [14, 55, 114].

False-negative reactions can be expected due to technical problems of the patch tests (low concentration or wrong vehicle, deficient skin penetration, wrong timing for performing patch testing), but there are certainly many other explanations for the absence of skin reactivity on patch testing: the responsible hapten is a drug metabolite that is not formed in the skin, the CADR is not an immune reaction or not dependent on the delayed hypersensitivity or, apart from drug exposure, concomitant factors (viral infection or concomitant drugs) are necessary for enhancing drug hypersensitivity [91].

For cotrimoxazol and acyclovir, patch tests in petrolatum are often negative, and DMSO or other penetration enhancers may be necessary to have positive patch tests. There is, for the moment, no explanation for the negative patch tests to allopurinol in delayed CADR, presumed to be immune-mediated, even when there is a positive accidental rechallenge. Although there is one report of a positive test in the study by Lammintausta and KorteKangas-Savolainen [13], in our experience, with more than 30 patients now, we did not observe a positive patch test with allopurinol, using low or high concentrations (1–20%), petrolatum or ethanol as excipient, with or without tape stripping, or even using one of its metabolites (8-oxypurinol) in different concentrations and vehicles [125].

26.3.6 Evaluating Cross-Reactivity on Patch Testing

Cross-reactivity observed among drugs in CADR can be studied, sometimes with very interesting results, at the patch test level.

It has been shown, in maculopapular exanthema, that amoxicillin and ampicillin always cross-react [54, 112], and this cross-reactivity is neither often extensive to benzilpenicillin or carbopenens [20], nor to cephalosporins except, eventually, cefalexin [126]. A similar pattern is usually confirmed by oral challenge [20, 49]. There is also frequent cross-reactivity among the cephalosporins

588 and the fluorquinolones [30] and between pristinamycin
589 and virginiamycin [50]. On the other hand, absence of
590 cross-reactions between tetrazepam and other benzodi-
591 azepines, particularly diazepam, was confirmed by patch
592 testing and oral provocation [89, 127].

593 Cross-reactions in fixed drug eruptions were also
594 found among different sulfonamides, among the three
595 piperazine derivatives (hydroxyzine, cetirizine, and levo-
596 cetirizine) [128], and oxicams (tenoxicam and piroxi-
597 cam) [66, 70]. This pattern of cross-reactivity between
598 piroxicam and tenoxicam, observed in all cases of fixed
599 drug eruptions studied, does not occur in other patterns
600 of CADR from oxicams. In patients with photosensitiv-
601 ity from piroxicam, tenoxicam is safe, as shown by pho-
602 topatch testing and drug challenge [40, 66].

603 Another particular pattern of cross reaction was shown
604 in photopatch tests between the arylpropionic NSAIDs,
605 ketoprofen, suprofen, and tiaprofenic acid in photoallerg-
606 ic contact dermatitis, and the lipid lowering agent, feno-
607 fibrate, in systemic photosensitivity [111, 129].

608 Unfortunately, there is not always correlation
609 between cross-reactivity in patch testing and oral prov-
610 ocation, as in patients who react only to carbamazepine
611 in the patch test, but do not tolerate other aromatic
612 antiepileptics [65].

Core Message

- › Patch tests with drugs are specific and can be important to study relevant cross-reactions between drugs.

26.4 Conclusions: Interpretation of Patch Test Results

613 Patch tests results in the study of drug eruptions should
614 be interpreted very carefully.

615 A positive test, using nonstandardized products, has to
616 be checked in controls to exclude false positive reactions.
617 A true positive test can be regarded as a sign of immuno-
618 logical reactivity of the patient and should be taken seri-
619 ously, if compatible with the history. Readministration of
620 the drug should be avoided as it can again elicit an adverse
621 reaction, usually, a more severe one.

622 A negative test result does not exclude hypersensi-
623 tivity or an adverse drug reaction. The test method
624 might not be adequate due to another pathomechanism,
625
626

627 the bioavailability of the test material might have been
628 insufficient, the wrong drug may have been tested (his-
629 tory and drug records can be surprisingly inaccurate),
630 or the right drug may have been tested but the allergen
631 could be a metabolite. Thus, a negative test result does
632 not allow a definitive conclusion.

633 If necessary, other tests have to be performed, such as
634 prick, scratch and intradermal skin tests or a challenge
635 (provocation) test [48]. In vitro tests for IgE (RAST)
636 exist for some drugs, as well as lymphocyte stimulation/
637 transformation tests. However, these tests are rarely
638 available or performed on a routine basis and their sen-
639 sitivity and specificity has yet to be precisely evaluated.

640 In conclusion, although many suspected patients
641 have negative reactions, it remains worthwhile to per-
642 form patch tests in patients with delayed CADR. They
643 can confirm a clinical imputability and avoid an even-
644 tual drug reintroduction with more severe conse-
645 quences. In very particular cases, they can also give
646 important information on cross-reacting drugs.

Core Message

- › It is worthwhile to perform patch tests in individual patients with a suspected drug eruption.

26.5 Classic Articles and Monographs

647 Barbaud A, Gonçalo M, Bruynzeel D, Bircher A
648 (2001) Guidelines for performing skin tests with drugs
649 in the investigation of cutaneous adverse drug reac-
650 tions. *Contact Derm* 45:321–328.
651

652 In detail is described how to perform skin tests in
653 CADR. The presented guidelines are proposed by the
654 Working party of the European Society of Contact
655 Dermatitis for the study of skin testing in investigating
656 CADR.

657 Kauppinen K, Alanko K, Hannuksela M, Maibach H
658 (eds) (1998) *Skin reactions to drugs*. CRC, Boca Raton

659 This book gives extensive information on cutane-
660 ous adverse reactions and challenge tests, how to per-
661 form skin tests and in whom.

662 Pichler WJ (ed) (2007) *Drug hypersensitivity*.
663 Karger AG, Basel

664 This book gives an extensive overview on the path-
665 omechanisms of especially type 4 allergy involvement
666 in adverse drug reactions.

- 668 1. Bruynzeel D, Maibach H (1998) Patch testing in systemic
669 drug eruptions. In: Kaupinen K, Alanko K, Hannuksela M,
670 Maibach H (eds) *Skin reactions to drugs*. CRC, Boca Raton,
671 pp 97–109
- 672 2. Roujeau J (1997) Drug induced skin reactions. In: Grobb
673 JJ, Stern RS, Mac Kie RM, Weinstock WA (eds)
674 *Epidemiology, causes and prevention of skin diseases*.
675 Blackwell, Oxford
- 676 3. Bigby M (2001) Rates of cutaneous reactions to drugs.
677 *Arch Dermatol* 137:765–770
- 678 4. Fiszenson-Alabala F, Auzeir V, Mahe E et al (2003) A
679 6-month prospective survey of cutaneous drug reactions in
680 a hospital setting. *Br J Dermatol* 149:1018–1022
- 681 5. Roujeau J (2005) Clinical heterogeneity of drug hypersen-
682 sitivity. *Toxicology* 209:123–129
- 683 6. Lacouture M, Melosky D (2007) Cutaneous reactions to
684 anticancer agents targeting the epidermal growth factor
685 receptor: a dermatology – oncology perspective. *Skin*
686 *Therapy Lett* 12:1–5
- 687 7. Friedmann P (2003) Mechanisms in cutaneous drug hyper-
688 sensibility. *Clin Exp Allergy* 33:861–872
- 689 8. Halevy S (2009) Acute generalized exanthematous pustu-
690 losis. *Curr Opin Allergy Clin Immunol* 9:322–328
- 691 9. Gonçalo M, Bruynzeel D (2008) Mechanisms in cutaneous
692 drug hypersensitivity reactions. In: Marzulli FN, Maibach
693 HI (eds) *Dermatotoxicology*, 7th edn. CRC, Boca Raton,
694 pp 259–268
- 695 10. Gonçalo M, Oliveira H, Monteiro C et al (1999) Allergic
696 and systemic contact dermatitis from estradiol. *Contact*
697 *Derm* 40:58–59
- 698 11. Veien N, Menné T, Maibach H (2008) Systemic contact-
699 type dermatitis. In: Marzulli FN, Maibach HI (eds)
700 *Dermatotoxicology*, 7th edn. CRC, Boca Raton, pp
701 139–153
- 702 12. Hausermann P, Harr T, Bircher A (2004) Baboon syndrome
703 resulting from systemic drugs: is there strife between
704 SDRIFE and allergic contact dermatitis syndrome? *Contact*
705 *Derm* 51:297–310
- 706 13. Lammintausta K, KorteKangas-Savolainen O (2005) The
707 usefulness of skin tests to prove drug hypersensitivity. *Br J*
708 *Dermatol* 152:968–974
- 709 14. Barbaud A (2005) Drug patch testing in systemic cutane-
710 ous drug allergy. *Toxicology* 209:209–216
- 711 15. Barbaud A, Gonçalo M, Bircher A, Bruynzeel D (2001)
712 Guidelines for performing skin tests with drugs in the
713 investigation of cutaneous adverse drug reactions. *Contact*
714 *Derm* 45:321–328
- 715 16. Bruynzeel D, Von Blomberg-Van der Flier M, Scheper R
716 et al (1985) Allergy for penicillin and the relevance of epi-
717 cutaneous tests. *Dermatologica* 171:429–434
- 718 17. Elzagallaai A, Knowles S, Rieder M et al (2009) Patch test-
719 ing in the diagnosis of anticonvulsivant hypersensitivity
720 syndrome. A systematic review. *Drug Safety* 32:391–408
- 721 18. Phillips E, Mallal S (2009) HLA and drug-induced toxicity.
722 *Curr Opin Mol Ther* 11:231–242
- 723 19. Phillips E, Mallal S (2009) Successful translation of phar-
724 macogenetics into the clinic: the abacavir example. *Mol*
725 *Diagn Ther* 13:1–9
- 726 20. Blanca M, Romano A, Torres M et al (2009) Update on the
727 evaluation of hypersensitivity reactions to betalactams.
728 *Allergy* 64:183–193
- 729 21. Hari Y, Frutig-Schnyder K, Hurni M et al (2001) T cell
730 involvement in cutaneous drug eruptions. *Clin Exp Allergy*
731 31:1398–1408
- 732 22. Pichler W (2003) Delayed drug hypersensitivity reactions.
733 *Ann Intern Med* 139:683–693
- 734 23. Pichler W, Tilch J (2004) The lymphocyte transformation
735 test in the diagnosis of drug hypersensitivity. *Allergy*
736 59:809–820
- 737 24. Bircher A (1999) Drug-induced urticaria and angioedema
738 caused by non-IgE mediated pathomechanisms. *Eur J*
739 *Dermatol* 9:657–663
- 740 25. Yawalkar N, Hari Y, Frutig K et al (2000) T cells isolated
741 from positive epicutaneous test reactions to amoxicillin and
742 ceftriaxone are drug specific and cytotoxic. *J Invest*
743 *Dermatol* 115:647–652
- 744 26. Britschgi M, Steiner U, Schmid S et al (2001) T-cell
745 involvement in drug-induced acute generalized exanthem-
746 atic pustulosis. *J Clin Invest* 107:1433–1441
- 747 27. Kuechler P, Britschgi M, Schmid S et al (2004) Cytotoxic
748 mechanisms in different forms of T-cell-mediated drug
749 allergies. *Allergy* 59:613–622
- 750 28. Naisbitt D (2004) Drug hypersensitivity reactions in
751 the skin: understanding mechanisms and the develop-
752 ment of diagnostic and predictive tests. *Toxicology* 194:
753 179–196
- 754 29. Pichler W (2002) Pharmacological interactions of drugs
755 with antigen-specific immune receptors: the p-i concept.
756 *Curr Opin Allergy Clin Immunol* 2:301–305
- 757 30. Schmid D, Depta J, Pichler W (2006) T cell-mediated
758 hypersensitivity to quinolones: mechanisms and cross-
759 reactivity. *Clin Exp Allergy* 36:59–69
- 760 31. Posadas S, Pichler W (2007) Delayed drug hypersensitivity
761 reactions: new concepts. *Clin Exp Allergy* 7:898–999
- 762 32. Choquet-Kastylevsky G, Intrator L, Chenal C et al (1998)
763 Increased levels of interleukin-5 are associated with the
764 generation of eosinophilia in drug-induced hypersensitivity
765 syndrome. *Br J Dermatol* 139:1026–1032
- 766 33. Kardoun S, Sidoroff A, Valleyrie-Allanore L et al (2007)
767 Variability in the clinical pattern of cutaneous side-effects
768 of drugs with systemic symptoms: does a DRESS syn-
769 drome really exist? *Br J Dermatol* 156:609–612
- 770 34. Britschgi M, Pichler W (2002) Acute generalized exan-
771 thematous pustulosis. Role of cytotoxic T cells in pustule
772 formation: a clue to neutrophil-mediated processes orches-
773 trated by T cells. *Curr Opin Allergy Clin Immunol* 2:
774 325–331
- 775 35. Thomas E, Bellón T, Barranco P et al (2008) Acute gener-
776 alized exanthematous pustulosis due to tetrazepam. *J*
777 *Investig Allergol Clin Immunol* 18:119
- 778 36. Nassif A, Bensussan A, Boumsell L et al (2004) Toxic epi-
779 dermal necrolysis: effector cells are drug specific cytotoxic
780 T cells. *J Allergy Clin Immunol* 114:1209–1215
- 781 37. Nassif A, Moslehi H, Le Gouvello S et al (2004) Evaluation
782 of the potential role of cytokines in toxic epidermal necroly-
783 sis. *J Invest Dermatol* 123:850–855
- 784 38. Shiohara T, Mizukawa Y, Teraki Y (2002) Pathophysiology
785 of fixed drug eruption: the role of skin-resident T cells.
786 *Curr Opin Allergy Clin Immunol* 2:317–323

- 787 39. Mizukawa Y, Yamazaki Y, Shiohara T (2008) In vivo
788 dynamics of intraepidermal CD8+ T cells and CD4+ T
789 cells during the evolution of fixed drug eruption. *Br J*
790 *Dermatol* 158:1230–1238
- 791 40. Gonçalves M, Figueiredo A, Tavares P et al (1992)
792 Photosensitivity to piroxicam: absence of cross reaction
793 with tenoxicam. *Contact Derm* 27:287–290
- 794 41. Gonçalves M (1998) Exploration dans les photo-allergies
795 médicamenteuses. In: GERDA. Progrès en Dermato-
796 Allergologie. John Libbey Eurotext, Nancy, pp 67–74
- 797 42. Oliveira H, Gonçalves M, Figueiredo A (1996) Photosensitivity
798 from lomefloxacin. A clinical and photobiological study.
799 *Photoderm Photoimmunol Photomed* 16:116–120
- 800 43. Griem P, Wulferink M, Sachs B et al (1998) Allergic and
801 autoimmune reactions to xenobiotics: how do they arise?
802 *Immunol Today* 19:133–141
- 803 44. Moore N, Biour M, Paux G et al (1985) Adverse drug
804 reaction monitoring: doing it the French way. *Lancet*
805 9:1056–1058
- 806 45. Lammintausta K, KorteKangas-Savolainen O (2005) Oral
807 challenge in suspected cutaneous adverse drug reactions.
808 *Acta Derm Venerol* 85:491–496
- 809 46. Alanko K, Kauppinen K (1998) Diagnosis of drug eruptions:
810 clinical evaluation and drug challenge. In: Kauppinen
811 K, Alanko K, Hannuksela M, Maibach H (eds) *Skin reactions to drugs*. CRC, Boca Raton, pp 75–79
- 812 47. Merk H (2005) Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines. *Toxicology* 209: 217–220
- 813 48. Hannuksela M (1998) Skin testing in drug hypersensitivity.
814 In: Kauppinen K, Alanko K, Hannuksela M, Maibach H
815 (eds) *Skin reactions to drugs*. CRC, Boca Raton
- 816 49. Torres M, Sánchez-Sabaté E, Alvarez J et al (2004) Skin
817 test evaluation in non-immediate allergic reactions to penicillins. *Allergy* 59:219–224
- 818 50. Barbaud A, Tréchet P, Weber-Muller F et al (2004) Drug
819 skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergists. *Contact Derm* 50:22–26
- 820 51. Barbaud A, Reichert-Penetrat S, Tréchet P et al (1998) The
821 use of skin testing in the investigation of cutaneous adverse
822 drug reactions. *Br J Dermatol* 139:49–58
- 823 52. Osawa J, Naito S, Aihara M et al (1990) Evaluation of skin
824 test reactions in patients with non-immediate type drug
825 eruptions. *J Dermatol* 17:235–239
- 826 53. Barbaud A (2002) Tests cutanés dans l'investigation des
827 toxidermies: de la physiopathologie aux résultats des investigations. *Thérapie* 57:258–262
- 828 54. Gonçalves M, Fernandes B, Oliveira H, Figueiredo A (2000)
829 Epicutaneous patch testing in drug eruptions. *Contact Derm*
830 42:S22
- 831 55. Barbaud A (2009) Skin testing in delayed reactions to
832 drugs. *Immunol Allergy Clin North Am* 29:517–535
- 833 56. Sidoroff A, Halevy S, Bavnick J et al (2001) Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. *J Cutan Pathol* 28:113–119
- 834 57. Buettiker U, Keller M, Pichler W et al (2006) Oral prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group A confirmed by epicutaneous testing and lymphocyte transformation tests. *Dermatology* 213:40–43
- 835 58. Schmid S, Kuechler P, Britschgi M et al (2002) Acute generalized exanthematous pustulosis. Role of cytotoxic T cells in pustule formation. *Am J Pathology* 161:2079–2086
- 836 59. Gonçalves M, Figueiredo A, Poiares-Baptista A (1991) Pustulose exantemática aguda generalizada. Dois casos clínicos e revisão da literatura. *Med Cut ILA* 19:81–85
- 837 60. Wolkenstein P, Chosidow O, Fléchet M et al (1996) Patch testing in severe cutaneous adverse drug reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis. *Contact Derm* 35:234–236
- 838 61. Serra D, Mariano A, Gonçalves M, Figueiredo A (2009) Acute exanthematic pustulosis, psoriasis and drugs. In *Proceedings of 10th International Congress of Dermatology-ICD*. Prague
- 839 62. Hughes C, Foisy M, Dewhurst N et al (2008) Abacavir hypersensitivity reaction: an update. *Ann Pharmacother* 42:387–396
- 840 63. Phillips E, Sullivan J, Knowles S, Shear N (2002) Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. *AIDS* 16:2223–2225
- 841 64. Santiago F, Gonçalves M, Vieira R et al (2010) Epicutaneous patch testing in the diagnosis of drug hypersensitivity syndrome (DRESS). *Contact Derm* 62(1):47–53
- 842 65. Santiago F, Gonçalves M, Brites M et al (2008) Drug hypersensitivity syndrome (DRESS): what patch tests can reveal us. *Contact Derm* 58:S17
- 843 66. Gonçalves M, Oliveira H, Fernandes B et al (2002) Topical provocation in fixed drug eruption on nonsteroidal anti-inflammatory drugs. *Exogenous Dermatol* 1:81–86
- 844 67. Lee A (1998) Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. *Contact Derm* 38:258–260
- 845 68. Alanko K (1994) Topical provocation of fixed drug eruption. A study of 30 patients. *Contact Derm* 31:25–27
- 846 69. Robalo-Cordeiro M, Gonçalves M, Fernandes B et al (2000) Positive lesional patch tests in fixed drug eruptions from nimesulide. *Contact Derm* 43:307
- 847 70. Oliveira H, Gonçalves M, Reis J, Figueiredo A (1999) Fixed drug eruption to piroxicam. Positive patch tests with cross-sensitivity to tenoxicam. *J Dermatolog Treat* 10:209–212
- 848 71. Devleeschouwer V, Roelandts R, Garmyn M, Goossens A (2008) Allergic and photoallergic contact dermatitis from ketoprofen: results of (photo) patch testing and follow-up of 42 patients. *Contact Derm* 58:159–166
- 849 72. Asensio T, Sanchis M, Sánchez P, Vega J, Garcia J (2008) Photocontact dermatitis because of oral dexamethasone. *Contact Derm* 58:59–60
- 850 73. Serra D, Gonçalves M, Figueiredo A (2008) Two decades of cutaneous adverse drug reactions from piroxicam. *Contact Derm* 58:S35
- 851 74. Vasconcelos C, Magina S, Quirino P, Barros M, Mesquita-Guimarães J (1997) Cutaneous drug reactions to piroxicam. *Contact Derm* 39:145
- 852 75. Varela P, Amorim I, Massa A et al (1998) Piroxicam-beta-cyclodextrin and photosensitivity reactions. *Contact Derm* 38:229
- 853 76. Youn J, Lee H, Yeo U, Lee Y (1993) Piroxicam photosensitivity associated with vesicular hand dermatitis. *Clin Exp Dermatol* 18:52–54
- 854 77. Figueiredo A, Fontes Ribeiro C, Gonçalves S et al (1987) Piroxicam-induced photosensitivity. *Contact Derm* 17:73–79

- 909 78. Hindsén M, Zimerson E, Bruze M (2006) Photoallergic contact dermatitis from ketoprofen in Southern Sweden. *Contact Derm* 54:150–157
- 910 79. Kurumajin Y, Shono M (1992) Scarified photopatch testing in lomefloxacin photosensitivity. *Contact Derm* 26:5–10
- 911 80. Kimura M, Kawada A (1998) Photosensitivity induced by lomefloxacin with cross-photosensitivity to ciprofloxacin and feroxacin. *Contact Derm* 38:130
- 912 81. Vilaplana J, Romaguera C, Azón A, Lecha M (1998) Flutamide photosensitivity-residual vitiliginous lesions. *Contact Derm* 38:68–70
- 913 82. Martín-Lázaro J, Buján J, Arrondo A et al (2004) Is photopatch testing useful in the investigation of photosensitivity due to flutamide? *Contact Derm* 50:325–326
- 914 83. Alanko K (1993) Patch testing in cutaneous reactions caused by carbamazepine. *Contact Derm* 29:254–247
- 915 84. Camarasa J (1985) Patch test diagnosis of exfoliative dermatitis due to carbamazepine. *Contact Derm* 12:49
- 916 85. Puig L, Nadal C, Fernández-Figueras M, Alomar A (1996) Carbamazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. *Contact Derm* 34:435–437
- 917 86. Silva R, Machado A, Brandão M, Gonçalo S (1982) Patch test diagnosis in carbamazepine erythroderma. *Contact Derm* 45:283–284
- 918 87. Camarasa J, Serra-Baldrich E (1990) Tetrazepam allergy detected by patch test. *Contact Derm* 22:246
- 919 88. Sánchez-Morillas L, Laguna-Martínez J, Reaño-Matos M et al (2008) Systemic dermatitis due to tetrazepam. *J Invest Allergol Clin Immunol* 18:404–406
- 920 89. Pirker C, Mistic A, Brinkmeier T, Frosch P (2002) Tetrazepam drug sensitivity – usefulness of the patch test. *Contact Derm* 47:135–138
- 921 90. Shear N, Milpied B, Bruynzeel D, Phillips E (2009) A review of drug patch testing and implications for HIV clinicians. *AIDS* 22:999–1007
- 922 91. Renn C, Straff W, DorfMüller A et al (2002) Amoxicillin-induced rash in young adults with infectious mononucleosis: demonstration of drug specific reactivity. *Br J Dermatol* 147:1166–1170
- 923 92. Gonzalo-Garijo M, Rodríguez-Nevado I, Argila D (2006) Patch tests for diagnosis of delayed hypersensitivity to cephalosporins. *Allergol et Immunopathol* 34:39–41
- 924 93. Canelas M, Cardoso J, Gonçalo M, Figueiredo A (2008) Patch tests in the study of cutaneous drug reactions in erysipelas. *Contact Derm* 58:S18
- 925 94. Seitz C, Bröcker E, Trautmann A (2009) Allergy diagnostic testing in clindamycin-induced skin reactions. *Int Arch Allergy Immunol* 149:246–250
- 926 95. Lammintausta K, Tokola R, Kalimo K (2002) Cutaneous adverse reactions to clindamycin: results of skin testing and oral exposure. *Br J Dermatol* 146:643–648
- 927 96. Gonzalo-Garijo M, Pérez Calderón R, Argila Fernández-Durán D, Rangel Mayoral J (2005) Cutaneous reactions due to diltiazem and cross reactivity with other calcium channel blockers. *Allergol et Immunopathol* 33:328–340
- 928 97. Sousa-Basto A, Azenha A, Duarte M, Pardal-Oliveira F (1993) Generalized cutaneous reaction to diltiazem. *Contact Derm* 29:44–45
- 929 98. Lachapelle J, Tennstedt D (1998) Les tests épicutanés dans les txidermies médicamenteuses. In: *Progrès en Dermatologie Allergologie*. John Libbey Eurotext, Nancy, pp 57–66
- 930 99. Scherer K, Tsakiris D, Bircher A (2008) Hypersensitivity reactions to anticoagulant drugs. *Curr Pharm Des* 14:2863–2873
- 931 100. Koch P (2003) Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. *Contact Derm* 49:276–280
- 932 101. Isaksson M, Persson L (1998) Contact allergy to hydrocortisone and systemic contact dermatitis from prednisolone with tolerance of betamethasone. *Am J Contact Dermat* 9:136–138
- 933 102. Whitmore S (1995) Delayed systemic allergic reactions to corticosteroids. *Contact Derm* 32:193–198
- 934 103. Beck M, Marot L, Nicolas J et al (2009) Allergic hypersensitivity to topical and systemic corticosteroids: a review. *Allergy* 64:978–994
- 935 104. Barranco P, Rodríguez A, de Barrio M et al (2004) Sympathomimetic drug allergy: cross-reactivity study by patch test. *Am J Clin Dermatol* 5:351–355
- 936 105. Dalmau J, Serra-Baldrich E, Roé E et al (2006) Skin reaction to hydroxyzine (Atarax): patch test utility. *Contact Derm* 54:216–217
- 937 106. Ash S, Scheman A (1997) Systemic contact dermatitis to hydroxyzine. *Am J Contact Dermat* 8:2–5
- 938 107. Bruynzeel D, Van Ketel W (1989) Patch testing in drug eruptions. *Semin Dermatol* 8:196–203
- 939 108. Barbaud A, Tréchet P, Reichert-Penetrat S et al (2001) The usefulness of patch testing on the previously most severely affected site in a cutaneous adverse drug reaction to tetrazepam. *Contact Derm* 44:259–260
- 940 109. Klein C, Trautmann A, Zillikens D, Bröcker E (1995) Patch testing in an unusual case of toxic epidermal necrolysis. *Contact Derm* 33:448–449
- 941 110. Bruynzeel D, Ferguson J, Andersen K et al (2004) Photopatch testing: a consensus methodology for Europe. *J EADV* 18:679–682
- 942 111. Cardoso J, Canelas M, Gonçalo M, Figueiredo A (2009) Photopatch testing with an extended series of photoallergens. A 5-year study. *Contact Derm* 60:314–319
- 943 112. Gonçalo M, Coelho S, Figueiredo A (2006) Ascertaining patch test concentration in cutaneous adverse drug reactions to aminopenicillins and carbamazepine. *J Invest Dermatol* 126:S67
- 944 113. Özkaya-Bayazit E, Bayazit H, Özarmagan G (1999) Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. *Contact Derm* 41:185–189
- 945 114. Barbaud A, Tréchet P, Reichert-Penetrat S et al (1999) Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. *Contact Derm* 45:265–268
- 946 115. Verecken P, Birringer C, Knitelius A et al (1998) Sensitisation to benzyl alcohol: a possible cause of “corticosteroid allergy”. *Contact Derm* 38:106
- 947 116. Shmunis E (1984) Allergic dermatitis to benzyl alcohol in an injectable solution. *Arch Dermatol* 120:1200–1201
- 948 117. Schäfer T, Enders F, Przybilla B (1995) Sensitization to thimerosal and previous vaccination. *Contact Derm* 32:114–116
- 949 968
- 950 969
- 951 970
- 952 971
- 953 972
- 954 973
- 955 974
- 956 975
- 957 976
- 958 977
- 959 978
- 960 979
- 961 980
- 962 981
- 963 982
- 964 983
- 965 984
- 966 985
- 967 986
- 968 987
- 969 988
- 970 989
- 971 990
- 972 991
- 973 992
- 974 993
- 975 994
- 976 995
- 977 996
- 978 997
- 979 998
- 980 999
- 981 1000
- 982 1001
- 983 1002
- 984 1003
- 985 1004
- 986 1005
- 987 1006
- 988 1007
- 989 1008
- 990 1009
- 991 1010
- 992 1011
- 993 1012
- 994 1013
- 995 1014
- 996 1015
- 997 1016
- 998 1017
- 999 1018
- 1000 1019
- 1001 1020
- 1002 1021
- 1003 1022
- 1004 1023
- 1005 1024
- 1006 1025
- 1007 1026

- 1027 118. Mashiah J, Brenner S (2003) A systemic reaction to patch 1048
 1028 testing for the evaluation of acute generalized exanthema- 1049
 1029 tous pustulosis. *Arch Dermatol* 139:1181–1183 1050
 1030 119. Vaillant L, Camenen I, Lorette G (1989) Patch testing with 1051
 1031 carbamazepine: reinduction of an exfoliative dermatitis. 1052
 1032 *Arch Dermatol* 125:299 1053
 1033 120. Pietzcker F, Kuner V (1975) Anaphylaxie nach epicutanem 1054
 1034 Ampicillin-Test. *Z Hautkr* 50:437–440 1055
 1035 121. Maucher O (1972) Anaphylaktische Reaktionen beim 1056
 1036 Epicutanest. *Hautartz* 23:139–140 1057
 1037 122. Jonker M, Bruynzeel D (2003) Anaphylactic reaction by 1058
 1038 patch testing with diclofenac. *Contact Derm* 49:114–115 1059
 1039 123. Van Ketel W (1975) Patch testing in penicillin allergy. 1060
 1040 *Contact Derm* 1:253–254 1061
 1041 124. Barbaud A, Bene M, Schmutz J et al (1997) Role of delayed 1062
 1042 cellular hypersensitivity and adhesion molecules in macu- 1063
 1043 lopapular rashes induced by amoxycillin. *Arch Dermatol* 1064
 1044 133:481–486 1065
 1045 125. Vieira R, Gonçalo M, Figueiredo A (2004) Patch testing 1066
 1046 with allopurinol and oxypurinol in drug eruptions. *Contact*
 1047 *Derm* 50:156
126. Schiavino D, Nucera E, de Pasquale T et al (2006) Delayed 1048
 allergy to aminopenicillins: clinical and immunological 1049
 findings. *Int J Immunopathol Pharmacol* 19:831–840 1050
 127. Barbaud A, Girault P, Schmutz J et al (2009) No cross- 1051
 reactions between tetrazepam and other benzodiazepines: a 1052
 possible chemical explanation. *Contact Derm* 61: 1053
 53–56 1054
 128. Cravo M, Gonçalo M, Figueiredo A (2007) Fixed drug 1055
 eruption to cetirizine with positive lesional patch tests to 1056
 the three piperazine derivatives. *Int J Dermatol* 1057
 46:760–762 1058
 129. LeCoz C, Bottleander A, Scrivener J et al (1998) 1059
 Photocontact dermatitis from ketoprofen and tiaprofenic 1060
 acid: cross-reactivity study in 12 consecutive patients. 1061
Contact Derm 38:245–252 1062
 130. Bégaud B, Evreux J, Jouglard J, Lagier G (1985) Imputa- 1063
 tion of the unexpected or toxic effects of drugs. Actualiza- 1064
 tion of the method used in France. *Thérapie* 40: 1065
 111–118 1066

Uncorrected Proof

Author Queries

Chapter No.: 26

Query	Details Required	Author's Response
AU1	Kindly provide institutional details.	
AU2	Ref. [144] is cited in the text but not given in the list. Kindly provide the details of the same.	
AU3	Please check whether the edit is ok.	
AU4	The reference given under "Classic Articles and Monographs" is treated as such. Please check.	
AU5	Following references is not cited in text [130]. Kindly provide the citation.	